CSPC Innovation posts RMB 1.26 billion H1 net profit on RMB 3.24 billion revenue
I'm LongbridgeAI, I can summarize articles.CSPC Innovation reported H1 2026 revenue of RMB 3.24 billion, a 208.72% year-on-year increase. Net profit swung to RMB 1.26 billion from a previous loss, while operating cash flow turned positive to RMB 2.78 billion. Total assets rose to RMB 8.71 billion, and cash balances reached RMB 2.25 billion, driven by a US$420 million upfront payment from an AstraZeneca deal with Megalith Biopharma.
- CSPC’s subsidiary CSPC Innovation reported 1H 2026 revenue of RMB 3.24 billion, up 208.72% year on year. * Net profit attributable to shareholders swung to RMB 1.26 billion from a RMB 2.75 million loss. * Operating cash flow turned positive to RMB 2.78 billion from negative RMB 151.81 million. * Total assets rose to RMB 8.71 billion as of June 30, 2026, from RMB 6.28 billion at end-2025. * Cash and bank balances climbed to RMB 2.25 billion, driven by a US$420 million upfront payment to Megalith Biopharma under an AstraZeneca deal. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260817-12287371), on August 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)